ZEALC Stock Overview
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Zealand Pharma A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr.622.25 |
| 52 Week High | kr.742.25 |
| 52 Week Low | kr.217.40 |
| Beta | 0.67 |
| 1 Month Change | 0.69% |
| 3 Month Change | n/a |
| 1 Year Change | 183.10% |
| 3 Year Change | 221.74% |
| 5 Year Change | 356.20% |
| Change since IPO | 911.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| ZEALC | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -0.4% | 3.8% | 2.0% |
| 1Y | 183.1% | -23.3% | 4.5% |
Return vs Industry: ZEALC exceeded the UK Biotechs industry which returned -23.3% over the past year.
Return vs Market: ZEALC exceeded the UK Market which returned 4.5% over the past year.
Price Volatility
| ZEALC volatility | |
|---|---|
| ZEALC Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: ZEALC has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ZEALC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 253 | Adam Steensberg | www.zealandpharma.com |
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
Zealand Pharma A/S Fundamentals Summary
| ZEALC fundamental statistics | |
|---|---|
| Market cap | kr.41.10b |
| Earnings (TTM) | -kr.703.74m |
| Revenue (TTM) | kr.342.79m |
119.9x
P/S Ratio-58.4x
P/E RatioIs ZEALC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZEALC income statement (TTM) | |
|---|---|
| Revenue | kr.342.79m |
| Cost of Revenue | kr.688.10m |
| Gross Profit | -kr.345.31m |
| Other Expenses | kr.358.43m |
| Earnings | -kr.703.74m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 16, 2024
| Earnings per share (EPS) | -11.30 |
| Gross Margin | -100.74% |
| Net Profit Margin | -205.30% |
| Debt/Equity Ratio | 0% |
How did ZEALC perform over the long term?
See historical performance and comparison